AIM
TRIL

Aigen Investment Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Aigen Investment Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,636
Closed -$167K – 1184
2020
Q2 		$167K Buy
+20,636
New +$128K 0.02% 728

Other funds holding TRIL

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Aigen Investment Management's TRIL Position: Q3 2020 in Review

Aigen Investment Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2020, closing a stake of 20,636 shares — an estimated $167K sold.

Aigen Investment Management first reported a position in TRIL in Q2 2020 and held it in 1 quarter. The position peaked at $167K in Q2 2020. 114 funds tracked by Wall St. Rank hold TRIL as of Q3 2020.

  • Aigen Investment Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2020 after selling out during the quarter.
  • Aigen Investment Management sold 20,636 Trillium Therapeutics Inc. shares in Q3 2020, an estimated $167K.
  • Aigen Investment Management first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 1 quarter.
  • Aigen Investment Management's Trillium Therapeutics Inc. position peaked at $167K in Q2 2020.
  • 114 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2020.

Based on Aigen Investment Management's 13F filing for Q3 2020, filed 6 Nov 2020.